The drug development landscape has long been challenged by high costs, protracted timelines, and a high failure rate in clinical trials, often attributable to safety or efficacy failures not predicted by traditional animal models. NAMs, including complex in vitro models (CIVMs), microphysiological systems, organ-on-a-chip platforms, and advanced computational modeling, have emerged as revolutionary technologies that simulate human physiological responses with unprecedented accuracy. These systems replicate organ-level functions by integrating multiple cell types, three-dimensional tissue architecture, fluid dynamics, and biomechanical forces, providing human-relevant data that surpasses the predictive capacity of animal models.

Pharmaceutical industry stakeholders have progressively integrated NAMs into research workflows, recognizing the potential for these tools to bridge preclinical and clinical research gaps. Concurrently, regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have publicly committed to advancing NAMs as a regulatory priority, endorsing their use to improve the reliability and relevance of drug safety and efficacy assessments. Despite this regulatory encouragement, a critical obstacle remains: the absence of harmonized qualification standards that define the validation and application of NAMs across various contexts within drug development.

NAMs-DC is designed specifically to address this pivotal challenge, facilitating a collaborative ecosystem wherein developers, regulators, and end users converge to standardize qualification frameworks. This initiative focuses particularly on complex in vitro models, aiming to produce consensus-driven qualification criteria that can be universally applied. By fostering a precompetitive environment, the coalition mitigates fragmented validation efforts and promotes data and knowledge sharing, thereby accelerating the maturation and regulatory acceptance of NAMs technologies.

Under the stewardship of C-Path, NAMs-DC will develop rigorous, transparent qualification frameworks that empower end users—ranging from pharmaceutical companies to biotechnology firms—to confidently evaluate and select methods tailored to their unique contexts of use. Through a structured approach, developers will gain clarity on evidentiary requirements, and regulators will benefit from consistent, science-based evaluations, improving the integration of NAMs into regulatory decision-making processes.

Klaus Romero, M.D., M.S., FCP, CEO of C-Path, underscores the significance of this coalition as a watershed moment for the drug development sector. He emphasizes that the field has long required a neutral convener capable of bridging the gap between innovative scientific methods and the regulatory rigor needed to validate and qualify these tools. C-Path’s initiative is poised to facilitate multi-stakeholder collaboration, harnessing the combined expertise of developers, sponsors, regulators, and patient advocacy groups to transition from isolated technological breakthroughs toward a coordinated pathway for regulatory readiness.

One of the coalition’s essential contributions is the establishment of uniform qualification standards that substantially reduce redundant validation efforts among developers. This streamlining enables regulators to evaluate methodologies with enhanced consistency and confidence. The standardized framework articulates clear criteria for assessing the suitability of NAMs in broader applications, whether for interrogating hepatotoxicity, modeling myocardial function, evaluating drug permeation across biological barriers, or simulating disease-specific tissue responses. By doing so, NAMs-DC enhances regulatory dialogue, ensuring that qualification is underpinned by robust, reproducible scientific evidence.

Graham Marsh, Ph.D., C-Path’s scientific director and lead of NAMs-DC, highlights how developers of NAMs technologies, despite remarkable independent advances, have faced a fragmented regulatory qualification landscape. The coalition offers a structured forum for sharing best practices, aligning evidence generation methodologies, and creating a unified interface with regulatory bodies worldwide. This effort aims to cultivate a qualification paradigm that is transparent, grounded in rigorous science, and conducive to accelerating the regulatory incorporation of NAMs in drug development pipelines.

NAMs-DC’s founding membership embodies a diverse cross-section of organizations dedicated to advancing human-relevant drug discovery using experimental, computational, and patient-centered platforms. Members include pioneering developers such as CN Bio, Curi Bio, Emulate, InSphero, Modelus, Revalia Bio, VivoSphere, and the Myhre Syndrome Foundation. This eclectic mix represents a comprehensive spectrum of technological expertise, from organ-on-a-chip and microphysiological system development to disease modeling and computational simulations, reflecting the coalition’s commitment to encompassing broad technological modalities.

The coalition’s launch anticipates the MPS World Summit, where C-Path intends to engage the wider microphysiological systems community, elucidate NAMs-DC’s objectives, and invite further stakeholder participation. Prospective coalition members interested in contributing to this groundbreaking initiative may learn more and inquire about membership through the official website at c-path.org/nams-dc and by contacting coalition leaders Graham Marsh (gmarsh@c-path.org) and Samantha Wilkins (swilkins@c-path.org).

Founded in 2005 as a public-private partnership in response to the FDA’s Critical Path Initiative, Critical Path Institute maintains a global leadership role in facilitating collaborations that accelerate pharmaceutical innovation. With a robust network encompassing more than 1,600 scientists and regulatory officials worldwide, C-Path has generated influential consortia and projects that underpin advances in biomarker development, clinical trial simulation, and now, new approach methodologies. The institute’s global headquarters reside in Tucson, Arizona, with a European subsidiary based in Amsterdam, Netherlands, positioning it at the nexus of regulatory and scientific communities influential to drug development.

The emergence of NAMs-DC represents a critical evolution in the trajectory of regulatory science, blending technological innovation with regulatory pragmatism. By consolidating disparate development pathways and fostering a shared commitment to qualification science, the coalition is strategically positioned to unlock the full potential of human-relevant models in improving drug safety and efficacy evaluation. This initiative promises to catalyze a shift away from traditional reliance on animal models, ushering in an era where NAMs are routinely integrated into regulatory frameworks and everyday pharmaceutical research and development.

As the coalition grows, its impact is anticipated to reverberate across all facets of drug development, from early candidate screening to late-stage clinical validation. The promise of NAMs-DC lies not only in expediting regulatory acceptance but also in enhancing patient safety, reducing animal testing, and enabling more precise mechanistic understanding of drug actions within human biology. These advances collectively herald a new paradigm in biomedical innovation where science, regulation, and patient needs harmoniously converge.

Subject of Research:
New Approach Methodologies (NAMs) including complex in vitro models, microphysiological systems, organ chips, and computational models in drug development and regulatory qualification.

Article Title:
Critical Path Institute Launches NAMs Developer Coalition to Accelerate Regulatory Qualification of Innovative Toxicology and Drug Discovery Tools

News Publication Date:
May 19, 2026

Web References:
https://c-path.org/nams-dc

Keywords:
New Approach Methodologies, NAMs, complex in vitro models, microphysiological systems, drug discovery, regulatory science, drug development, qualification framework, Critical Path Institute, organ-on-a-chip, computational modeling, pharmaceutical innovation

Hepatocellular carcinoma remains one of the deadliest cancers worldwide due to its aggressive nature and limited treatment options. One of the critical challenges in studying HCC has been the inability to faithfully replicate the tumor’s microenvironment ex vivo, which includes not only cancer cells but also surrounding stromal cells, immune components, and the extracellular matrix milieu. Traditional two-dimensional culture systems fail to offer the spatial and biochemical complexity required to understand tumor-stroma interactions, immune modulation, and drug responses. The newly developed microenvironment-on-a-chip overcomes these obstacles by integrating multiple cell types within a dynamically perfused microfluidic device that recapitulates HCC’s structural and functional attributes.

At its core, the chip technology advances beyond static culture by introducing a finely tuned microfluidic network that simulates blood flow conditions, enabling nutrient and oxygen gradients similar to those found in vivo. This feature is crucial since tumor hypoxia and metabolic heterogeneity significantly influence HCC progression and therapeutic resistance. By incorporating liver-specific endothelial cells, stellate cells, and immune cells alongside carcinoma cells, the model allows for real-time assessment of cellular crosstalk under physiologically relevant shear stress and chemical gradients. Such dynamic interactions are pivotal in tumor growth, angiogenesis, and immune evasion.

The study highlights detailed characterization of the tumor microenvironment simulated on the chip, including extracellular matrix remodeling and cytokine profiles characteristic of liver malignancies. Using high-resolution imaging and transcriptomic analyses, the researchers verified that the tumor cells on-chip expressed hallmark molecular signatures of HCC and exhibited phenotypic behaviors such as invasiveness and proliferation rates comparable to clinical observations. Intriguingly, immune cell infiltration patterns were also faithfully mirrored, providing novel insights into the tumor-immune interface that are difficult to capture with conventional models.

By harnessing this technology, researchers demonstrated the ability to simulate and dissect the multifaceted responses of HCC tumors to various chemotherapeutic agents and immunotherapies. Rather than relying on static endpoint measurements, the chip enables longitudinal monitoring of drug efficacy and resistance evolution by tracking changes in cell viability, migration, and secretome dynamics over time. This capability ushers in a new era of personalized medicine approaches for liver cancer, where treatments can be tailored and optimized using patient-derived cells within these microengineered platforms.

Incorporating patient-specific biopsies into the organ-on-a-chip system opens doors for precision oncology applications. It empowers clinicians and researchers to generate bespoke tumor models that account for genetic and epigenetic heterogeneity, ultimately predicting individual patient responses to therapy with a level of accuracy unattainable by current preclinical models. Moreover, the scalability of the chip design promises potential for high-throughput drug screening, accelerating the discovery of novel anticancer compounds and combination regimens that are effective against resistant HCC subtypes.

The integration of microengineering, cell biology, and computational modeling was critical to the success of this platform. Sophisticated design considerations ensured optimal cell compartmentalization, mechanical properties consistent with hepatic tissue, and modulation of biochemical signaling pathways to authentically mimic the chronic inflammatory and fibrotic cues that often accompany hepatocellular carcinoma development. These technical refinements reflect a maturation of organ-on-a-chip technology from proof-of-concept to application-ready systems in cancer biology.

Furthermore, the microfluidic chip also facilitates exploration of metastasis and cancer stem cell niches within HCC. By manipulating spatial configurations and fluid shear forces, the study elucidates mechanisms by which tumor cells detach, invade surrounding matrices, and potentially intravasate into bloodstream analogs within the device. Understanding these steps under controlled conditions lays foundational work for strategic intervention points that may inhibit HCC dissemination and improve patient prognoses.

The multidisciplinary approach adopted by the authors merges experimental data with computational analyses of signaling networks, metabolic fluxes, and immune cell dynamics, paving the way for predictive modeling of tumor evolution and therapeutic outcomes. These insights provide a systems-level perspective crucial for designing next-generation therapeutics that target not just tumor cells, but the entire ecosystem that sustains malignancy and mediates drug resistance.

Importantly, this development addresses ethical and logistical drawbacks of animal models by providing human-relevant results without the complexity and variability often seen in in vivo systems. This paradigm shift aligns with global efforts to reduce animal testing and enhance translational fidelity from bench to bedside, ultimately accelerating clinical advancements for HCC patients worldwide.

Looking forward, the authors suggest that continued refinement of the model—including integration of vasculature-on-a-chip components, immune checkpoint modulations, and real-time biosensors—could further elevate the platform’s utility. Such enhancements will enable comprehensive dissection of therapeutic mechanisms, synergy effects, and emergent resistance patterns with temporal resolution previously unattainable, heralding a transformative era in cancer research.

This microenvironment-on-a-chip represents not only a technological triumph but also a conceptual leap in oncology, fundamentally redefining how complex liver tumors can be studied in controlled yet biologically faithful settings. The convergence of this platform with personalized medicine, high-throughput screening, and computational oncology promises to deliver breakthroughs in diagnosis, prognosis, and treatment strategies that save lives and improve quality of life for millions affected by hepatocellular carcinoma.

In light of these findings, the broader scientific community is poised to embrace organ-on-chip systems as indispensable tools for studying tumor biology. As the study by Mocellin and colleagues demonstrates, bridging the gap between microengineering and cancer biology opens fertile ground for innovation with profound clinical implications.

Ultimately, this advance underscores the vital importance of interdisciplinary collaboration to tackle the formidable challenge presented by hepatocellular carcinoma—a malignancy notorious for its complexity and therapeutic intractability. With sustained research and development spurred by this new model, a future where HCC can be routinely studied, understood, and effectively managed at the individual patient level draws increasingly near.

Subject of Research: Modeling hepatocellular carcinoma and its tumor microenvironment using organ-on-a-chip technology.

Article Title: Modeling hepatocellular carcinoma and its microenvironment on a chip.

Article References:

Mocellin, O., Treillard, S., Robinson, A. et al. Modeling hepatocellular carcinoma and its microenvironment on a chip.
Cell Death Discov. (2025). https://doi.org/10.1038/s41420-025-02917-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02917-8

The award ceremony took place during the MRS Spring Meeting held in Seattle, Washington, where Dr. Khademhosseini also delivered a keynote address detailing recent advances in engineered tissues for regenerative medicine applications. His presentation highlighted the innovative strides his lab has made in developing biomimetic materials that effectively recapitulate the complex cellular microenvironments necessary for tissue growth and repair, setting new standards for translational biomedical research.

Dr. Khademhosseini’s pioneering research integrates principles from materials science, microfabrication, and bioengineering to create engineered tissue constructs with unprecedented functionality. By leveraging microtechnology techniques such as photolithography and soft lithography, his team fabricates microstructured biomaterials that mimic the extracellular matrix’s mechanical and biochemical properties, enabling precise control over cell behavior and tissue morphogenesis.

At the heart of his contributions lies the development of organ-on-a-chip platforms, which simulate human organ physiology in vitro with heightened accuracy. These microfluidic systems are poised to revolutionize personalized medicine by providing reliable models for drug screening and disease modeling, thereby reducing reliance on animal testing and enhancing the predictability of clinical outcomes. Such platforms embody the convergence of materials science and bioengineering aimed at addressing complex health challenges.

Moreover, Dr. Khademhosseini’s work with regenerative biomaterials is instrumental in advancing therapeutic strategies for tissue repair. His lab has engineered novel hydrogels and polymeric scaffolds functionalized with biochemical cues that promote cell adhesion, proliferation, and differentiation. These materials harness the dynamic interplay between mechanical forces and cellular signaling pathways, facilitating the reconstruction of damaged tissues in a controlled and efficient manner.

Beyond the innovation in biomaterials design, the Terasaki Institute under Dr. Khademhosseini’s leadership is pioneering microfabrication approaches that enable high-throughput manufacturing of biomimetic tissues. This scalability represents a transformative step, allowing for widespread application in both research and clinical settings, thereby accelerating the translation of materials-based solutions from bench to bedside.

Dr. Khademhosseini emphasizes the interdisciplinary nature of his achievements, reflecting a collaborative ethos that bridges engineering, biology, and medicine. His commitment to fostering multi-disciplinary partnerships has catalyzed the development of novel materials that respond dynamically to cellular environments, epitomizing the future of precision regenerative therapies.

His innovative methodologies also include utilizing stimuli-responsive materials that can adapt their properties in response to environmental triggers such as pH, temperature, or enzymatic activity. These smart biomaterials provide versatile platforms for controlled drug delivery and tissue modulation, enhancing therapeutic efficacy and reducing side effects.

The significance of Dr. Khademhosseini’s work extends deeply into the realm of drug discovery, where engineered tissue models offer intricate insights into human physiology and pathophysiology. By accurately replicating organ-level functions, these tissue constructs enable pharmaceutical researchers to identify drug responses and toxicities earlier and more effectively, streamlining the development pipeline.

Furthermore, his leadership has propelled advances in biomedical microdevices that integrate sensors and actuators within engineered tissues, enabling real-time monitoring and modulation of cellular functions. This integration of bioelectronics with biomaterials paves the way for creating “living” devices capable of autonomously responding to biological signals, representing a futuristic paradigm in medicine.

The Materials Research Society recognized Dr. Khademhosseini for his trailblazing contributions that not only push the boundaries of materials science but also translate into tangible healthcare innovations with profound societal impact. His visionary approach exemplifies the power of materials engineering to address pressing medical challenges and improve patient outcomes globally.

Reflecting on this honor, Dr. Khademhosseini remarked that the award celebrates the collective efforts of his talented colleagues and the vibrant research community at TIBI. He reiterated the institute’s unwavering dedication to advancing the frontiers of biomaterials and regenerative medicine, forging solutions that hold promise for millions worldwide.

As the interdisciplinary landscape of biomedical innovation continues to evolve, Dr. Khademhosseini’s work stands at the forefront, inspiring future generations of scientists and engineers to harness the potential of materials science. His achievements illuminate a path toward a future where engineered tissues and regenerative therapies become integral components of personalized healthcare.

Subject of Research: Biomaterials science, tissue engineering, regenerative medicine, engineered tissues, microfabrication, organ-on-a-chip technologies
Article Title: Dr. Ali Khademhosseini Awarded 2025 Materials Research Society Mid-Career Researcher Award for Pioneering Biomedical Innovation
News Publication Date: April 23, 2025
Web References: https://www.mrs.org/spring2025 https://terasaki.org
Image Credits: Terasaki Institute
Keywords: Science careers, Materials testing, Discovery research, Social research, Tissue engineering, Regenerative medicine, Biomaterials, Research organizations